Sino Biological has announced that its new location in Houston, Texas, is now open, expanding the company geographically.
List view / Grid view
Sino Biological Inc.
To support disease research, Sino Biological has deposited reagents for the Omicron variant to BEI Resources.
Sino Biological has developed recombinant Omicron Spike RBD protein and antibody reacting with Omicron to support the study of Omicron variant.
Sino Biological, Inc. has just launched a panel of research reagents for the newly identified Omicron variant (B.1.1.529) of the SARS-CoV-2 virus, which quickly raised concerns around the world due to the high number of mutations it carries, particularly the 30-plus mutations on the Spike protein.
Sino Biological is an international reagent supplier and service provider. The company specialises in recombinant protein production and antibody development.
A panel of SARS-CoV-2 reagents (e.g. antigens, antibodies, and kits) and influenza antigens have been developed to support the development of vaccines.
Sino Biological has developed 1,000+ cytokines and receptors, including growth factors, cytokines, chemokines, interferons, interleukins, etc.
Sino Biological has developed 80+ mutant proteins covering the newest mutations identified in SARS-CoV-2 variants, such as UK's B.1.1.7, Brazil's P.1.